Evidence map›Paper›PMID 35677318›Full record

ArticleTherapeutic advances in medical oncology2022

Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.

Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S de Bono

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01308580 (Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01308580 phase3completednot on this map

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

TypeinterventionalSponsorSanofiRan2011 to 2015Enrolled1,200ConditionsProstate CancerArmsCabazitaxel (XRP6258), Prednisone (or Prednisolone)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 5 countries.

Alexander MeiselDepartment of Nuclear Medicine Zurich, University Hospital of Zurich, Raemistr. 100, 8091 Zurich, Switzerland.
Ronald de WitMedical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Stephane OudardService d'Oncologie Médicale, Georges Pompidou European Hospital, Rene Descartes University, Paris, France.
Oliver SartorMedicine and Urology, Tulane Cancer Center, New Orleans, LA, USA.
Frank Stenner-LiewenDepartment of Oncology, University Hospital of Basel, Basel, Switzerland.
Zhenming ShunOncology, Sanofi, Basking Ridge, NJ, USA.
Meredith FosterGlobal Medical Affairs Oncology, Sanofi, Cambridge, MA, USA.
Ayse OzatilganGlobal Medical Affairs Oncology, Sanofi, Cambridge, MA, USA.
Mario EisenbergerThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Johann S de BonoDivision of Clinical Studies, Drug Development Unit, The Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, London, UK.
AVEO Oncology (United States) · USÉcole Polytechnique Fédérale de Lausanne · CHErasmus MC · NLHôpital Européen Georges-Pompidou · FRJohns Hopkins Hospital · USRoyal Marsden NHS Foundation Trust · GBSanofi (United States) · USTulane Medical Center · USUniversity Hospital of Basel · CH

Funding

Medical Research Council MR/W018217/1
6 · The paper itself

Abstract

Background and purpose: Chemotherapy-induced neutropenia and neutrophil-to-lymphocyte ratio (NLR) are potentially useful prognostic markers in patients with metastatic castration-resistant prostate cancer (mCRPC). This post hoc analysis investigated whether these markers can be utilized for dose considerations and evaluated the prognostic impact of leukocyte subtypes. Patients and methods: PROSELICA assessed the non-inferiority of cabazitaxel 20 mg/m Results: PROSELICA confirmed the negative prognostic value of increased baseline NLR [⩾3, hazard ratio (HR) 1.40; Conclusions: Grade ⩾ 3 neutropenia was the only leukocyte-based biomarker associated with all key outcome parameters in mCRPC patients receiving cabazitaxel and might be able to overcome the negative prognostic effect of baseline neutrophilia. NCT number: NCT01308580.

Indexed as

cabazitaxelmCRPCneutropenianeutrophilianeutrophil-to-lymphocyte ratioprostate cancer

Identifiers

PMID35677318
PMCPMC9168856
OpenAlexW4285245545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.